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Abstract
Classically, the development and launching of a new drug is a highly time consuming, 
tedious and expensive process involving following fundamental steps: (1) Identification 
of cause of Disease and Search for target site. (2) Search and Optimisation of active com-
pound, that is, the Drug Lead. (3) Testing of Drug in Animals (pre-clinical phase). (4) 
Clinical Trials. (5) Approval of New Drug by Competent authority and availability of the 
drug. Drug discovery and development process involves around 10–15 years of investi-
gation period and incredibly high cost and investment. This process also involves partic-
ipation of experts from various disciplines and fields. Therefore, the new approaches are 
obligatory to be developed not only to expedite the process but also to ensure the launch 
of safer and effective drug. Over this background, the importance of experimental wis-
dom and holistic approach is intensifying to offer good base as an attractive discovery 
engine. Natural product drug discovery, ethno-pharmacology, traditional and attractive 
medicines are re-emerging as new strategic options. In the past decade, the number of 
new chemical entity (NCG) in drug development channel is declining markedly might 
have led to the rekindling of interest in emergence of natural product as new drug leads. 
The novel natural products can be optimised on the basis of their biological activities 
using highly sophisticated combinatorial biosynthetic techniques, microbial genomes 
and screening process.
Keywords: natural products, drug leads, microorganism and marine source
1. Introduction
Drug discovery and development is mainly concerned with new chemical entity with biologi-
cal activity. It works on enhancing the properties of drugs used in the treatment of different 
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Figure 1. Complete process of drug discovery from plants.
medical conditions. Classically, the development and launching of a new drug is a highly time-
consuming, tedious and expensive process involving under mentioned fundamental steps:
• Identification of cause of Disease and Search for target site
• Search and Optimisation of active compound, that is, the Drug Lead
• Testing of Drug in Animals (pre-clinical phase)
• Clinical Trials
• Approval of New Drug by Competent authority and availability in market.
Drug discovery leading to strong and doable lead candidate always remained exigent assign-
ment for scientists. In fact experts accomplish the task by transforming the screening hit com-
pound to a suitable drug candidate. The journey of new drug to the market is considerably 
long and takes about 10–15 years of investigation period. Therefore, the new approaches are 
obligatory to be developed not only to expedite the process but also to ensure the launch of 
safer and effective drug [1].
Over this background, the importance of experimental wisdom and holistic approach is inten-
sifying to offer good base as an attractive discovery engine. Natural product drug discovery, 
ethno-pharmacology, traditional and attractive medicines are re-emerging as new strategic 
options. In the past decade, the number of new chemical entity (NCE) in drug development 
channel is declining markedly might have led to the rekindling of interest in the emergence 
of natural product new drug leads. The novel-natural products can be optimised on the basis 
of their biological activities using highly sophisticated combinatorial biosynthetic techniques, 
microbial genomes and screening process (Figure 1).
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Since ages the natural products have been the source of medicinal agents and will continue 
to play crucial role in the human health through the expanded investigation of world biodi-
versity. World Health Organization (WHO) reports that about 80% of the world’s population 
depends on traditional medicine for their health care. Further, at least 119 important chemical 
substances have been derived from 90 plant species [2].
With the advent of theory of drug-receptor action, the scientists concluded that it is the iso-
lated compound from the plant extract that is responsible for pharmacological action. This 
leads to new era in pharmacology and area of new drug research. The classical example is 
morphine (from opium) and digoxin (from Digitalis purpurea). A number of modern med-
icines have been obtained from natural resources such as plants, microorganisms, marine 
organisms and minerals. Nature continues to be a main source of molecular diversity, which 
through the pursuit of multidisciplinary, international collaborative research can result in the 
development of promising lead compounds [3].
2. Natural product as new drug lead
Lead identification/optimisation is the one of the most important steps in drug develop-
ment following the biological target identification. The properties of a drug can be enhanced 
or potentiated by making certain modifications/alterations in its chemical structure. Drug 
efficacy, potency, selectivity and pharmacokinetic parameters can be improved by making 
necessary structural changes. The chemical structure is the key to lead compound iden-
tification. After the lead compound identification, the next step is the study of ADMET 
that is absorption, distribution, metabolism, excertion and toxicology of the probable drug 
lead. If these studies are positive and satisfactory, the compound is nontoxic and non-
mutagenic, then the compound is turned to be potential lead compound. This may then be 
developed as new drug. (Figure 2). Lead compound is a chemical compound that shows 
desired pharmacological activity and may initiate the development of new chemical entity, 
relevant compound. These are actually the starting molecule for the new drug. Newer tech-
niques can be adopted to accelerate the enhancement in the compounds pharmacological 
properties.
The promising sources of lead compound and novel drugs are:
• Natural products
• Chemical libraries
• Computational Medicinal Chemistry
Recently, there has been a keen interest in natural product research as the traditional method 
of drug discovery failed to yield desired lead compound particularly in areas such as immu-
nosuppressant, anti-infective and metabolic diseases. Natural product research continues to 
explore a variety of lead chemical structures that can be used as a template for new drug by 
the pharmaceutical industry. This is also evident that new approaches to enhance the joint 
drug discovery and development process would be expected to take place basically from 
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Figure 3. Drug leads and drug development.
innovation in drug target elucidation along with lead structure discovery. There are new tech-
nologies like automated separation techniques, high throughput screening and combinatorial 
chemistry are powerful and revolutionising drug discovery. (Figure 3).
Figure 2. Process of lead selections and identification.
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Apart from comparing with other drug discovery methods, natural products are still provid-
ing their fair share of new clinical candidates and drugs. These said compounds were still a 
significant source of new drugs, especially in the anticancer, anti-infective, antihypertensive, 
immune-suppression and neurological disease therapeutic areas [4–7]. The natural products 
used as drug lead are shown in Figure 4.
2.1. Plants
Plants are affluent source of pharmaceuticals as well as drug leads. They are the natural labo-
ratories where the simple chemical skeleton is transformed to complex chemical structures. 
The natural metabolites are far better than the synthesised metabolites in biological efficacy. 
A survey of plant-derived drugs in countries that host the WHO—Traditional medicinal 
Centres indicated that out of 122 compound identified 80% were derived from 94 plant spe-
cies. Some of the drugs obtained in this approach are: sodium cromoglycate, a bronchodila-
tor from khellin (Ammi visnaga), Metformin, an antidiabetic from galegine (Galega officinalis), 
verapamil a antihypertensive from papaverine (Papaver somniferum), aspirin an analgesic from 
salicin (willow bark), atorvastatin from mevastatin (Penicillium citrinum), (Figure 5). Malaria 
remains one of the biggest challenges faced by the mankind, and there is a continuous search 
for an effective drug. The isolation of quinine from cinchona bark was reported in 1820 by the 
French pharmacists Caventou and Pelletier. Quinine formed the basis for the synthesis of the 
commonly used antimalarial drugs. Another antimalarial drug developed from plant lead is 
artemisinin obtained from Artemisia annua. There analogues are used in many countries for 
the treatment of malaria.
Other noteworthy drugs developed from traditional medicinal plants are: Reserpine an anti-
hypertensive drug from Rauvolfia serpentina, Ephedrine from Ephedra sinica used as the basis 
for the synthesis of the anti-asthmatic drug salbutamol and salmeterol, tubocurarine a muscle 
Figure 4. Natural products as drug leads.
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relaxant, from Curare species. A number of anticancer agents have been obtained from plants: 
vinblastine and vincristine from Catharanthus roseus and two clinically active compounds eto-
poside and teniposide, Paclitexel most exhilarating anticancer derived from Taxus species. 
(Figure 6).
In addition, recently, various other chemically active agents have gained attention and impor-
tantly placed in the arsenal of plant-derived anticancer agents. These are topotecan, irinote-
can (CPT-11); belotecan and also their analogues 9-amino and 9-nitro camptochecin. These 
are semi-synthetic in nature, derived from camptochecin isolated from a Chinese ornamental 
tree camptotheca acuminate. One of the first plant-derived tubulin interactive compounds 
recently entered clinical trials, maytansine from the Ethiopian tree Maytenus serrata. This plant 
granted a new lease of life “warhead” (slightly modified), on a monoclonal antibody. The nat-
ural product chemists wondered if the compound was microbial in origin due to its similarity 
to the “ansa” antibiotic such as the rifamycins. Scientists at Takeda during 1977 reported very 
closely resembled the maytansinoids structure. Thereafter, compounds isolated from bacte-
rium which was renamed as Actinosynnema pretiosum in fact similar to those isolated from 
other plant genera [8].
Figure 5. Drugs developed from plant lead molecule.
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2.2. Animals
Amphibians, reptiles and humans have been a fine source of drug. Epibatidine is a potent 
analgesic obtained from the skin of epipedobates tricolour (A frog). This drug is several times 
stronger than morphine. But the main snag is that the therapeutic dose of the drug is more 
close to its toxic dose that drives the development of synthetic analogue. Epibatidine has 
turned out to be important lead compound for potential novel painkillers. Teprotide isolated 
from the venom of the snake pit viper, Bothrops jararaca led to the design and synthesis of ACE 
inhibitor Captopril used in the management of hypertension. Another noteworthy finding 
Figure 6. Plant-derived drugs.
Integrated Approach to Nature as Source of New Drug Lead
http://dx.doi.org/10.5772/intechopen.74961
35
S.No. Anti-tumour antibiotic Source
1 Bleomycin Streptomyces verticillus
2 Mitomycin Streptomyces caespitosus
3 Daunomycin Streptomyces peucetius
4 Doxorubicin Streptomyces peucetius var. caesius.
Table 1. Antitumor antibiotics.
was the isolation of exendin-4 from the venom of Gila monster, Heloderma suspectum that leads 
to the development of Byetta an injectable antidiabetic drug to control type 2 diabetes. In 2009, 
a notable peptide having closeness to Human GLP-1 was approved for similar indication in 
Europe and then in Japan, in 2010, in the USA, under the name liraglutide [9] (Figure 7).
2.3. Micro organisms
The discovery of Penicillin from Penicillium notatum in 1929 by Fleming steers a new era in 
medicine “The Golden Era of Antibiotics” and accelerated the investigation of nature for bio-
active agents. The microorganisms are the productive source of dissimilar bioactive metabo-
lites and have turned out to be a vital source of drugs in Pharmaceutical industry. These are 
antibacterial agents: Penicillin from Penicillium species, cephalosporins from Cephalosporium 
acremonium, tetracycline, chloramphenicol, aminoglycosides, rafamycin, and so on. In addi-
tion to this immunosuppressive agents like cyclosporins from trichoderma, cholesterol low-
ering drug such as mevastatin (compactin; from Penicillium species) and lovastatin from 
Aspergillus species, anthelmintics and antiparasitic drugs like ivermectins from Streptomyces 
species are all originated from microorganisms [9].
Among the anticancer drugs, anticancer antibiotics plays a significant role in the chemother-
apy. These are given in Table 1.
2.4. Marine organisms
Seventy five percent of the earth surface has been covered by water, but there is limited 
research as far as pharmacology of marine organisms is concerned. Many of these are still 
Figure 7. Drug from snake venom.
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unexplored. Marine environment characterises various diverse resources towards new 
drugs to fight most major diseases like malaria and cancer. Marine environment also sig-
nifies an ecological resource consisting of a variety of aquatic plants and animals. Such 
aquatic organisms are screened for immunomodulatory, antibacterial, antifungal, anti-
inflammatory, antimicrobial, neuroprotective, anticancer, analgesic and antimalarial prop-
erties. These aquatic organisms are used for new drug developments mostly all over the 
world. Thus, under the marine pharmacology, there is further scope for research on the 
drugs of marine origin [10]. Marine pharmacology can be classified on the basis of source 
of the candidate drug:
• Genetically engineered marine organisms
• Manufacture of pharmaceuticals and nutraceuticals of marine origin
• Chemicals produced by or found in marine organisms shown to have a wide variety of 
applications as pharmaceuticals.
Classification of marine drugs on the basis of their action (Table 2).
Some of the drugs of marine origin approved for human use in different parts of the world 
are as follows (Table 3).
Given underneath are certain marine drugs that are now under Clinical Phase III trial (Table 4).
There are some marine drugs that are undergoing Phase II trial (Table 5).
Few drugs are also undergoing Clinical Phase I trial (Table 6).
Class Marine drugs
Antibacterial Eicosapentaenoic acid, isolated from Phaeodactylum tricornutum active against gram 
positive and gram negative bacteria.
Anti-inflammatory The extracts and other parts of a Mediterranean sponge species Spongia officinalis showed 
anti-inflammatory activity in vivo.
Neuroprotective Extracts of South Indian green seaweed Ulva reticulate having neuroprotective action.
Antiparasitic Extracts of Sarcotragus sp. known as Tunisian sponge showed in-vitro anti-leishmanial 
activity.
Antiviral agents Exo-polysaccharide extracted from the Celtodoryx girardae has Anti-herpes simplex virus-1 
(HSV) activity.
Anticancer Bryostatin, obtained from the Bryozoan, Bugula neritina, some forms from sponges and 
tunicates have cytotoxicity.
Analgesic Ziconotide, first US FDA approved analgesic of marine origin.
Antimicrobial The cephalosporins are well-known antimicrobial agents with a marine source of origin.
Antimalarial activity Isonitrile containing antimalarial molecules have been extracted from the Acanthella sp., 
a Japanese sponge.
Table 2. Classification of marine drugs.
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Approved marine drug
Cytarabine It is FDA approved and mainly used in different types of leukaemia, including acute myelocytic 
leukaemia, lymphocytic leukaemia, meningeal leukaemia, and chronic myelogenous leukaemia.
Vidarabine It is FDA approved used in recurrent epithelial keratitis caused by HSV type 1 and 2, acute kerato-
conjunctivitis, and also for superficial keratitis
Ziconotide Ziconotide, FDA approved has shown potential as an analgesic.
Trabectedin A marine product extracted from Ecteinascidia turbinate. First anticancer molecule of marine 
origin got approval in EU for use in soft-tissue sarcoma and in relapsed cases of platinum-sensitive 
ovarian cancer
Table 3. Approved drugs of marine origin.
Marine drugs in clinical Phase III trial
Eribulin mesylate (E7389) 
or halichondrin B
It is a polyether macrolide natural molecule originally extracted from marine sponges, 
with potent anticancer activity reported in preclinical animal models. Eribulin is a 
potent molecule which produces irreversible antimitotic activity leading to cell death by 
apoptotic pathway.
Soblidotin (auristatin PE 
or TZT-1027)
Is a synthetic derivative of the dolastatin backbone from dolastatin 10. It is a vascular 
disrupting agent causing the collapse of the vasculature inside the tumour, in addition 
to its tubulin inhibitory activity. It is undergoing trials in clinical Phases I, II, and III and 
companies are trying to use it as a weapon to specific monoclonal antibodies.
Tetrodotoxin Well-known “marine toxin”, and highly substituted guanidine-derivative is not an anti-
tumour agent, currently in Phase III trials as analgesic against inadequately controlled 
pain related to the cancer.
Table 4. Marine drugs in clinical Phase III trial.
Marine drugs in clinical Phase II trial
DMXBA (GTS-21) 
[3-(2,4-dimethoxybenzylidene) 
-anabaseine; GTS-21]
It is a synthetic imitative of anabaseine, an alkaloid found in many species 
of aquatic worms of phylum nemertea. It is reported to be beneficial 
for improving cognition and sensory gating deficiency in a variety of 
laboratory animals.
Plitidepsin It is a natural marine depsipeptide, currently obtained by total synthesis. 
It was primarily isolated from a tunicate Aplidium albicans found in the 
Mediterranean Sea. It is a highly potent apoptosis inducer.
Elisidepsin (PM02734) It is a novel cyclic peptide derived from marine sources belonging to the 
Kahalalide family. It is now in Phase II with proof of antitumor potency 
with positive therapeutic index.
PM00104 (Zalypsis) It is linked to jorumycin extracted from the Pacific nudibranch’s (Jorunna 
funebris) skin and mucus as well as from renieramiycins extracted from 
varieties of sponges and tunicates. Preclinical in vivo studies indicated 
high antitumor activity in cells of breast, prostate and renal cancers with a 
modest antitumor action on colon cancer cells.
Plinabulin (NPI-2358) It is a fully laboratory made analog of the natural product halimide 
originally derived from marine Aspergillus sp. CNC-139 and phenylahistin 
extracted from Aspergillus ustus. It inhibits the polymerisation of tubulin, 
resulting in destabilisation of the vascular endothelial cells of the tumour.
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3. Natural product drug discovery and development: an integrative 
approach
An integrative approach comprising various discovery tools and novel discipline would defi-
nitely endow with an input in natural product drug discovery and development. Natural 
product can be envisaged to remain an indispensable component in the development of new 
drug. According to Lutz natural product not only complement synthetic molecule, they also 
exhibit drug-related features unsurpassable by any synthetic compound. An important attri-
bute of natural product is their huge structure and chemical diversity. Another beneficial 
feature of natural product is their biological history. The natural products possess an inherent 
ability to interact with other molecules, which is a crucial precondition for making a drug. 
The natural product due to its sterically more complex structure exhibit advanced binding 
properly compared with synthetics. The natural products are perceived as “drug like-ness” 
and “biological friendliness” than totally synthetic molecule making them apposite lead 
candidates.
The process of drug discovery involves the identification of candidates, synthesis, screen-
ing, characterisation and assays for therapeutic efficacy, which in fact is a very lengthy and 
tedious process. Considering the success of natural products as source of new drugs, new 
technologies have emerged to facilitate the process. These technologies are combinatorial 
chemistry, high throughput screening (HTS), bioinformatics, proteomics and genomics. 
Marine drugs in clinical Phase II trial
ILX-651 (tasidotin or synthadotin) A synthetic derivative of dolastatin-15 and it inhibits assembly of tubulin. 
It is an orally active drug and has progressed to Phase II trials in different 
types of cancer.
Pseudopterosins A leading class of diterpene glycosides primarily extracted from the 
octocoral Pseudopterogorgia elisabethae. It is a strong phorbol myristate 
acetate inhibitor. In a double-blind, Phase II clinical trial, the drug was 
found to augment re-epithelialisation process in early wound repair 
process.
Table 5. Marine drugs in clinical Phase II trial.
Marine drugs in clinical Phase I trial
Leconotide (AM-336, 
ω-conotoxin CVID)
It is a peptide similar to Ziconotide and is undergoing Phase I trials for the treatment of 
cancer.
Enfortumab vedotin It is used in immunotherapy, and it is a combination of a fully human IgG1k antibody 
and monomethyl auristatin E.
Vorsetuzumab mafdotin 
(SGN-75)
An antibody-drug conjugate, with monomethyl-auristatin F attached to the anti-CD70 
monoclonal humanised antibody 1F6. This molecule is presently being evaluated for its 
value in relapsed and refractory non-Hodgkin’s lymphoma in Phase I clinical trials and 
also in metastatic renal cancer.
Table 6. Marine drugs in clinical Phase I trial.
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Other recently developed techniques are molecular diversity, compound library design, 
MMR based screening, QSAR and computer-aided drug design.
3.1. Combinatorial chemistry
Combinatorial chemistry involves the rapid synthesis or the computer simulation of a 
large number of different but often structurally related molecules or materials. In a com-
binatorial synthesis, the number of compounds made increases exponentially with the 
number of chemical steps. In a binary light-directed synthesis, 2n compounds can be 
made in n chemical steps. Combinatorial chemistry is especially common in computer 
aided drug design (CADD) and can be done online with web-based software, such as mole 
inspiration.
3.1.1. Principle of combinatorial chemistry
Combinatorial chemistry is a technique by which large numbers of structurally distinct mol-
ecules may be synthesised in a time and submitted for pharmacological assay. The key of 
combinatorial chemistry is that a large range of analogues is synthesised using the same reac-
tion conditions, the same reaction vessels. In this way, the chemist can synthesise many hun-
dreds or thousands of compounds in one time instead of preparing only a few by simple 
methodology.
The conventional approach of synthesis is
  A   +  B    →     AB 
In contrast to this approach, combinatorial chemistry offer the potential to make every combi-
nation of compound A1 to An with compound B1 to Bn.
The range of combinatorial techniques is highly diverse, and these products could be made 
individually in a parallel or in mixtures, using either solution or solid phase techniques.
Combinatorial Chemistry is used to synthesise large number of chemical compounds by com-
bining sets of building blocks. Each newly synthesised compound’s composition is slightly 
different from the previous one. A traditional chemist can synthesise 100–200 compounds 
per year. A combinatorial robotic system can produce in a year thousands or millions com-
pounds, which can be tested for potential drug candidates in a high-throughput screening 
process [11].
3.2. High throughput screening
High throughput screening is a standard method for hit discovery for scientific experimen-
tation in drug discovery and allied field. HTS uses robotics, data processing and control 
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software, liquid handling devices and sensitive detectors making researchers to quickly con-
duct the biochemical, genetic or pharmacological tests. Employing HTS, it is comparatively 
trouble-free and swift to identify active compounds. HTS is hassle free technique that collects 
large amount of experimental data in a relatively short time [11].
3.3. Bioinformatics, proteomics and genomics
Genomics and proteomics in combination with combinatorial chemistry and high-throughput 
screening are helping to bring forward an unparalleled number of potential lead compounds. 
Proteomics includes technologies for protein mapping that is separating, distinguishing and 
quantifying the proteins in samples and also identification and characterisation of specific 
protein. The main protein mapping technology currently in use is two-dimensional polyacryl-
amide gel electrophoresis (2D-PAGE) that can resolve up to 2000 proteins in single gel.
Genomics is an area within genetics that concerns the sequencing and analysis of an organ-
ism’s genome. The genome is the entire DNA content that is present within one cell of an 
organism. Experts in genomics strive to determine complete DNA sequences and perform 
genetic mapping to help understand disease. Since many diseases occurs due to failure of 
genes to perform correctly, genomics help to identify the genes involved in responsiveness to 
a given drug. Hence, genomics is an integral part of drug discovery [12].
4. Challenges with natural products
In spite of so many inherent advantages of these natural products for the synthesis of various 
molecules ranging from simple skeleton to highly complex chemical structures, they do have 
certain potential limitations.
• Drug discovery from natural products would eventually lead to its commercialisation. This 
may further burden the natural resource and consequently lead to undesirable environ-
mental concerns. While synthesis of active molecule could be an option, not every molecule 
is amenable for complete synthesis. Hence, certain degree of dependence on lead resource 
would continue, for example, anticancer agent like etoposide, docetaxel, paclitaxel. It is 
expected that around 25,000 plant species would cease to exit by the end of this century.
• Another issue, the IPR protection related to the natural products is creating some confusion 
because the lead compounds are based on some linkage to traditional uses.
These processes impede the pace of discovery process at various levels. Challenges in the new 
drug developments are mainly due to:
i. Existing prototype for drug discovery in large pharmaceutical industries.
ii. Technical limitation of natural products
Integrated Approach to Nature as Source of New Drug Lead
http://dx.doi.org/10.5772/intechopen.74961
41
According to Koehn and Carter, the unique feature/characters of the compound isolated from 
natural products are:
a. Increased steric complexity
b. Presence of large number chiral centres
c. Presence of greater number of oxygen atoms
d. Ratio of aromatic ring atoms to total heavy atoms, that is, low
e. Molecular rigidity is high
f. Wider distribution of molecular properties, such as molecular mass, O/w partition coef-
ficient and diversity of ring system [13].
It is presumed that large number of NP despite being biologically active and having favour-
able pharmacokinetic profile do not satisfy the criteria “drug likeness.” The challenge is of 
building a physio-chemical tuned natural products library in line c the lead generation to 
promote natural products to their full potential. Therefore, ultimately, the biggest challenge 
is to find alternative drug ability criteria for the compound of natural origin, as they do not 
fit “rule of five” for to be drug like. As per rule of five propagated by Lipinski [14], a drug 
candidate should have:
i. Less than 10 H bond acceptors
ii. Less than 5 H bond acceptors
iii. Mol, wet >500 Da
iv. PK of less than 5
5. Conclusion
Natural product drug discovery, ethno-pharmacology, traditional and attractive medicines 
are re-emerging as new strategic options. The chapter endeavoured that novel-natural prod-
ucts can be optimised on the basis of their biological activities using highly sophisticated 
combinatorial biosynthetic techniques, microbial genomes and screening process.
The chapter made efforts to provide short-lived imprint of the significance of natural products 
as bioactive molecules and also as pharmaceutical agents. On the advent of novel screening 
systems related to the discovery of genetic information accelerating the need to rapidly iden-
tify effective and novel lead structures as important necessity. It is certain that an important 
portion of these leads will remain to be resultant natural product.
As on today, comparative ease of access to plants now resulted in the discovery of a plant-
derived compounds, so far as the microbial sources are particularly important in the area 
of antibiotic. Further effort suggests, that marine organisms, and such group of organisms 
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not much published, the marine-sourced fungi shall perform progressively significant role in 
the future. This role especially when given the impressive advances in the power of organic 
synthesis to report the supply problems intrinsic with this source material. With the arrival of 
genetic techniques that permit the isolation and expression of biosynthetic cases in the future, 
microbes and their marine invertebrate hosts might better be the new frontier towards natural 
products lead discovery. Plant endophytes also offer stimulating new resource.
Forthcoming features of antibiotic discovery and development include somewhat from a dif-
ferent perspective, a significant number of issues referred to in this chapter. Together with 
these novel sources to refurbished phenotypic screens that employ high-content imaging sys-
tems and that can run in microliter volumes, it might enable investigators to speedily evaluate 
the activity of individual agents and their potential.
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